Latest Headlines

Latest Headlines

GlaxoSmithKline shutters lung cancer vaccine study on latest MAGE-A3 setback

Just days after announcing that investigators had red-flagged a high-profile Phase III study of the cancer vaccine MAGE-A3 after failing to hit two primary endpoints for non-small cell lung cancer, GlaxoSmithKline has decided to bring a last-stab effort to find a subpopulation of patients who could benefit from the therapy to a halt. GSK says it was not possible to find a genetically defined group of patients who responded.

Agenus stock jumps on Phase II brain cancer vaccine data

Agenus has fallen a long way since its stock briefly traded for $300 a share in 2000. The failure of its partner GlaxoSmithKline's cancer vaccine in September sent the stock tumbling 23% to $2.84 and it continued to drop in the following months. Now though, Agenus has good news to report.

Agenus mounts a comeback on positive results for its brain cancer vaccine

The cancer immunotherapy biotech Agenus has continued its march back from a big R&D setback earlier in the year, seeing its share price spike 36% this morning after posting positive results for a single-arm Phase II study of one of its brain cancer vaccines.

Agenus, Sanofi-NIH collaboration race to develop genital herpes vaccine

Agenus and a Sanofi-NIH collaboration both gave updates on their genital herpes vaccine candidates this week. The Agenus vaccine, HerpV, is leading the race, having met its primary endpoint in a Phase II trial of 80 subjects, 70 of whom received the treatment.

Brain cancer vaccine data gives Agenus' stock a boost

Agenus has had a topsy-turvy month. Its share price fell off a cliff after the GlaxoSmithKline vaccine that uses its adjuvant failed a Phase III trial, only to rally this week on the back of news about its own clinical candidate.

Agenus taps investors after upbeat PhII data for brain cancer vaccine

Agenus has struck a deal to raise about $6.5 million from institutional backers in a direct offering of common stock and warrants. The financing was announced a day after the Lexington, MA-based biotech company revealed that patients with glioblastoma multiforme, a cancer which attacks the brain, who took its experimental vaccine lived more than twice as long without their cancer getting worse than those on the standard of care.

Personalized brain cancer vaccine improves survival

Phase II data for Agenus' HSPPC-96 vaccine (also known as vitespen) showed glioblasoma patients living longer, which could offer a glimmer of hope.

Is Agenus on GSK's shopping list?

It's been a busy week or two for GlaxoSmithKline ($GSK)--the company has extended its agreement with Agenus ($AGEN), submitted two vaccines for approval and created a joint venture.

Agenus inks Oncophage cancer vaccine deal with Russian company

Cancer vaccine developer Agenus has inked a licensing, development and manufacturing technology transfer agreement with Russian drug company NewVac. Under the deal, NewVac gets to manufacture, market...

Agenus encouraged by early HerpV results

Lexington, MA-based Agenus reported promising Phase I results of its recombinant therapeutic vaccine HerpV for the treatment of genital herpes in a study published in the journal Vaccine. The